PatientPoint Company Growth, Stability & Outlook

PatientPoint holds a very strong competitive position within the point-of-care media industry. Its scale makes it the largest POC network in the space — reaching 124,000 healthcare providers across 30,000 locations through 145,000 digital devices, with 1 in 3 prescriptions written by a PatientPoint provider. That network includes some of the strongest prescribers in the country, giving the platform outsized influence at the exact moments patients and providers are making healthcare decisions together.

PatientPoint is also MRC accredited across its network, which gives advertisers confidence that campaigns are reaching intended audiences — a meaningful differentiator in an industry where measurement credibility is hard-won. That accreditation isn't just a badge; it's been tested directly. When a major pharmaceutical client left the point-of-care space after a competitor's dishonest practices damaged trust industry-wide, PatientPoint spent several years pursuing MRC accreditation the right way — and the client returned with significant new investment specifically because of it. And PatientPoint's renewal rates are exceptionally high, standing out not just within POC media but across the broader media industry.

That strength extends to how PatientPoint compares directly against its closest peers. Among direct point-of-care competitors, PatientPoint's 4.1 Glassdoor rating and 73% employee recommend rate outpace Phreesia (3.1 rating, 45% recommend) and Health Monitor Network (3.2 rating, 52% recommend) — and even ties CheckedUp, a physician-founded competitor with a genuinely compelling mission story, at 4.1. Against larger talent competitors vying for the same candidates, PatientPoint's numbers hold up just as well: 73% recommend versus Optum's 56%, CVS Health's 44%, and Deloitte's 74% — all while offering a mission-driven, flexible culture without the up-or-out intensity candidates often cite as a drawback of big-firm environments.

Outcomes data reinforces why brands and providers stay with the platform: PatientPoint's network is associated with a 45% increase in mammograms scheduled, a 30% increase in first fill rate, a 30% increase in consultation services, a 28% increase in flu vaccines, and a 45% increase in time on therapy — the kind of measurable impact that's difficult for less-established competitors to match at scale.

PatientPoint's growth trajectory is strong and accelerating. Revenue continues to grow year over year, driven by ongoing network expansion from the provider sales team and exceptional client retention and growth from the client sales team. That momentum is backed by Advent International and favorable trends across the healthcare media industry.

Recent product launches show that momentum translating into real market expansion. In March 2026, PatientPoint launched PatientPoint Health Audiences, a new programmatic-buying capability that gives pharmaceutical and consumer health brands flexible, data-driven access to premium advertising inventory across the company's waiting room network — addressing a market where more than 90% of pharma digital display spend is expected to shift to programmatic buying. That same month, PatientPoint also launched its Consumer Health Network, extending the company's reach beyond pharmaceutical brands into CPG, OTC, and wellness marketers — unlocking access to 350 million annual adult visits across more than 30,000 provider offices, including scaled reach into specific high-intent audiences like 200 million healthy agers, 31 million allergy sufferers, and 27 million GLP-1 users. Together, these two launches signal PatientPoint isn't just growing its existing footprint — it's actively building new categories of revenue on top of the network it already owns.

Hiring momentum backs this up operationally: PatientPoint has brought on close to 100 new hires year-to-date, with an average time-to-fill of 41 days and average time-to-hire of 29 days — fast enough to suggest the company is scaling deliberately rather than straining to keep pace with demand.

Some may point to the recent CEO transition as a concern, but the circumstances here are anything but typical turnover. In April 2026, President Trump appointed Sean Slovenski — PatientPoint's President and CEO — to serve as Deputy Director and Chief Operating Officer of the CDC, a national appointment and a genuine testament to the caliber of leadership PatientPoint has built. Rather than leave a gap, the company turned to Jim Lang, its longstanding Chairman of the Board, who stepped in as interim CEO to carry the company's current vision and strategy forward without disruption. That kind of continuity — leadership drawn from deep institutional knowledge rather than an outside hire scrambling to get up to speed — reflects the strength of PatientPoint's bench, not a gap in it.